Toggle light / dark theme

New article on immigration and AI in The Guardian. https://www.theguardian.com/technology/2016/dec/14/donald-tr…automation #future


All of this could be under threat if we are to take some of the comments the Trump campaign made in the run-up to the election at face value. The outspoken candidate claimed that Mark Zuckerberg’s push for specialist H1B visas (the main visa used to hire foreign talent to tech companies) was a threat to jobs for American women and minorities. Meanwhile, Trump’s chief strategist Steve Bannon suggested that Asians have too much power in Silicon Valley.

About a dozen members of Silicon Valley’s elite – including Apple CEO Tim Cook, Alphabet CEO Larry Page, Microsoft CEO Satya Nadella and Facebook COO Sheryl Sandberg – will meet with Trump in New York. The meeting is likely to provide an opportunity for them to highlight their concerns and priorities with the incoming administration.

Trump was critical of Silicon Valley business practices during his campaign – from wanting Apple to stop making phones in China to saying Amazon founder Jeff Bezos bought the Washington Post to exert political power and avoid paying taxes.

“If you look at the history of Silicon Valley, it’s clear that drawing on immigrants has been a big part of the vitality, creativity and success of that entrepreneurial melange,” said Marjory Blumenthal, senior policy analyst at Rand Corporation.

Read more

Senescent cell removal holds great potential but are all research approaches equal?


Some scientific commentary on senescent cell clearing (Senolytics) and the different approaches the research community is engaged in.

“Researchers are taking two broad approaches to cellular senescence at the present time. The first is to build therapies that can selectively destroy senescent cells, following the SENS rejuvenation model of periodic removal of damage. If the number of senescent cells is managed so as to keep that count low, then they will not cause further harm. This has the advantage of being straightforward and requiring little further research to put into practice. A range of demonstrated treatments and potential treatments already exist — gene therapies, immunotherapies, senolytic drugs, and so forth — and companies such as Oisin Biotechnologies and UNITY Biotechnology are bringing some of these technologies to the clinic.”

Read more

Synthetic biology meets senolytics at Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1


Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Dr. Aubrey de Grey from the SENS Research Foundation was kind enough to talk in support of CellAge and their campaign on Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1


Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Cellular senescence is a complicated process but here it is explained in a simple infographic. The removal of senescent cells (senolytics) is a very hot topic right now and it represents the arrival of the first of the SENS therapies.

CellAge is one of the companies engaged in senolytic research and they are running a campaign on Lifespan.io if you would like to learn more about them.

https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/


Lifespan.io / Life Extension Advocacy Foundation

Lilly announced today that CYRAMZA® (ramucirumab) has been approved by the Singapore Health Sciences Authority to treat people with advanced gastric cancer, whose cancer has progressed after prior chemotherapy. First country in ASEAN to approve the new biologic therapy that extends survival in patients with advanced stomach cancer after prior chemotherapy

CYRAMZA® (ramucirumab) is now available to Singaporeans living with advanced gastric cancer. The drug gained approval by Singapore’s Health Science’s Authority (HSA) earlier this year, marking the first regulatory approval in ASEAN. CYRAMZA is already available to patients in Japan, Korea, Taiwan and Hong Kong.

Read more

Are you an avid supporter of aging research and a keen longevity activist?
The Biogerontology Research Foundation is offering select summer internships for talented individuals. You’d join a passionate and supportive team in researching diagnostic, prognostic, and therapeutic strategies; advising a panel of investors in developing a roadmap to promote longevity science and related technologies across the globe.

The advertised positions are 3 month internships, with the possibility of continuing afterwards. Free accommodation will be provided for in London, alongside a negotiable salary.

The Biogerontology Research Foundation is a UK based think tank dedicated to aging research and accelerating its application worldwide.

Apply to: [email protected]


Are you an avid supporter of aging research and a keen longevity activist?

The Biogerontology Research Foundation is offering select summer internships for talented individuals. You €™d join a passionate and supportive team in researching diagnostic, prognostic, and therapeutic strategies; advising a panel of investors in developing a roadmap to promote longevity science and related technologies across the globe.

Read more